Cardiac biomarkers refer to proteins that are present in blood when the heart muscle is damaged or stressed. They help detect and monitor various heart conditions. The cardiac biomarkers market has been witnessing significant growth over the past few years driven by the rising incidence of cardiovascular diseases and growing elderly population worldwide who are more prone to cardiac issues. Furthermore, ongoing technological advancements are allowing for the development of more sensitive biomarkers that can enable the earlier detection of cardiac conditions.

Market Dynamics:

The global cardiac biomarkers market is driven by the increasing geriatric population, rising economic burden of cardiovascular diseases, growing adoption of point-of-care testing, and ongoing research & development. However, regulatory issues regarding the approval of new cardiac biomarkers, lack of awareness, and reluctant acceptance of new technologies pose challenges to market players. The market sees opportunities in developing economies due to increasing healthcare spending, growing diabetes and lifestyle disease burden, and emergence of local players. Key players are focusing on developing novel biomarker panels and portable testing devices for improved patient monitoring and management.

Key Features of the Study:

• This report provides an in-depth analysis of the global cardiac biomarkers market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global cardiac biomarkers market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Roche Diagnostics, Abbott Laboratories, Siemens Healthcare, bioMérieux, and Becton, Dickinson and Company.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global cardiac biomarkers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cardiac biomarkers market.

Detailed Segmentation-

• By Product Type:
  
  • Myocardial Muscle Creatine Kinase (CK MB)
  • Myoglobin
  • Troponins (T and I)  
  • Brain Natriuretic Peptide (BNPs) or NT-proBNP 
  • Ischemia-modified Albumin (IMA)
  • Others
• By Application:
  
  • Myocardial Infarction 35.5
  • Congestive Heart Failure,
  • Acute Coronary Syndrome,
  • Atherosclerosis, 
  • Others
  • Myocardial Infarction 35.5
  • Congestive Heart Failure,
•  By Location of Testing:
  • Laboratory Testing 70.1 %
  • Point of Care Testing
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Abbott Laboratories
  • Life Diagnostics
  • Roche Diagnostics
  • Siemens Healthineers
  • Danaher Corporation
  • Becton, Dickinson and Company (BD)
  • Bio-Rad Laboratories, Inc.
  • Thermo Fisher Scientific Inc.
  • PerkinElmer Inc.
  • bioMérieux SA
  • Randox Laboratories Ltd.
  • Ortho Clinical Diagnostics
  • Myriad RBM
  • DiaDexus Inc.
  • Response Biomedical Corp.
  • BG Medicine, Inc.
  • Boston Scientific Corporation
  • Cardiovascular Systems, Inc.
  • Quidel Corporation